Nuvo, partner win FDA approval

The FDA has approved a new osteoarthritis therapy developed by Covidien and Nuvo Research. The non-steroidal anti-inflammatory Pennsaid will be marketed for osteoarthritis symptoms in the knee. Nuvo owns the IP on the product and Covidien will handle commercialization in the U.S. They're looking to launch in the first half of the year. Story